AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - Seite 2

For more information about AiBtl and its products and services, please visit https://www.aibtlpharma.com/

Share valuations set forth herein are based on private negotiations between the parties and are not based on third-party or market prices.

About AiBtl BioPharma Inc. (AiBtl)

AiBtl is a US company registered in Delaware to integrate the health and resort industries. Additionally, the venture will capitalize on development revenues within the Asia Economic Development Zone, primarily through land lease income. With a focus on delivering cutting-edge AI-powered products and services, AiBtl is committed to driving innovation and shaping the future of AI across various industries. AiBtl's Licensed Products for MDD and ADHD from ABVC, with a $667M valuation by a third-party evaluation, are determined to work to strengthen its new drug development and business collaboration. https://www.aibtlpharma.com/

About TT Life Company

TT Life Company is a renowned player in the precision medicine industry, known for its expertise in designing and manufacturing innovative precision solutions that enhance consumers' lives. TT Life is a marketing and sales (direct sales) Company that produces its proprietary cell-related products, such as mitochondrion and cell-derived exosomes. It focuses on precision medicine and healthcare tailored to personal needs. The marketing team is well known in Asia, particularly in Malaysia. Its targeted sales in 2024 are set at $10M, with net profits of 11%. With a focus on combining style and functionality, TT Life Company is committed to delivering high-quality products that seamlessly integrate into everyday life. https://ttlifeglobal.com/

For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, the Company utilizes in-licensed medicine from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus, the Company intends to conduct global clinical trials through Phase III.